Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
29.31
-0.95 (-3.14%)
At close: Apr 25, 2024, 4:00 PM
28.38
-0.93 (-3.17%)
After-hours: Apr 25, 2024, 6:08 PM EDT
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for SUPN stock has a target of 41, which predicts an increase of 39.88% from the current stock price of 29.31.
Analyst Consensus: Buy
* Price targets were last updated on Feb 28, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for SUPN is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $45 → $41 | Buy | Maintains | $45 → $41 | +39.88% | Feb 28, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +46.71% | Nov 9, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $43 → $42 | Buy | Maintains | $43 → $42 | +43.30% | Oct 25, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $45 → $46 | Buy | Maintains | $45 → $46 | +56.94% | May 10, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $40 → $47 | Buy | Maintains | $40 → $47 | +60.35% | Jan 23, 2023 |
Financial Forecast
Revenue This Year
615.28M
from 607.52M
Increased by 1.28%
Revenue Next Year
634.14M
from 615.28M
Increased by 3.07%
EPS This Year
1.67
from 0.02
Increased by 8,247.02%
EPS Next Year
1.99
from 1.67
Increased by 18.94%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 647.7M | 694.8M | 774.7M | 887.3M | 945.0M |
| Avg | 615.3M | 634.1M | 709.5M | 845.2M | 918.0M |
| Low | 582.2M | 573.4M | 644.6M | 782.8M | 882.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.6% | 12.9% | 22.2% | 25.0% | 11.8% |
| Avg | 1.3% | 3.1% | 11.9% | 19.1% | 8.6% |
| Low | -4.2% | -6.8% | 1.7% | 10.3% | 4.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.89 | 2.68 | 3.53 | 4.57 | 5.35 |
| Avg | 1.67 | 1.99 | 2.86 | 4.41 | 5.20 |
| Low | 1.50 | 1.02 | 1.86 | 4.20 | 5.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9,350.0% | 60.4% | 77.7% | 59.7% | 21.5% |
| Avg | 8,247.0% | 18.9% | 44.0% | 54.1% | 18.1% |
| Low | 7,397.0% | -38.9% | -6.2% | 47.0% | 13.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.